Effect of varying contrast material iodine concentration and injection technique on the conspicuity of hepatocellular carcinoma during 64-section MDCT of patients with cirrhosis

Computed tomography image quality in patients with primary hepatocellular carcinoma: intraindividual comparison of contrast agent concentrations

Objective

This study aimed to assess the impact of the different concentrations of iodine contrast agents used on the quality of computed tomography (CT) images obtained intraindividually in hepatocellular carcinoma patients.

Methods

In this retrospective study, data from a cohort of 29 patients diagnosed with primary hepatocellular carcinoma who had undergone two preoperative CT-enhanced examinations within a 3-month timeframe were analyzed. Each patient was randomly assigned to receive either a low-concentration contrast agent (300 mg I/mL iohexol) or a high-concentration contrast agent (350 mg I/mL iohexol) for the first scan and the alternative contrast agent for the second scan. CT images of different liver regions of each patient were compared between low-and high-concentration scans using their before-and-after control design. Subjective image quality scores for portal vein images were also assessed.

Results

The findings of this study indicate that patients in the high-concentration group presented significantly elevated CT values across various anatomical regions, including the liver parenchyma, abdominal aorta, and hepatic portal vein, compared to those in the low-concentration group (p < 0.05). Moreover, the high-concentration group demonstrated superior subjective image ratings (p < 0.05). Nevertheless, there was no statistically significant difference in the CT values observed in liver cancer parenchyma scans at different phases between the two groups (p > 0.05).

Conclusion

In summary, using a high-concentration iodine contrast agent is efficient in enhancing the visual clarity of the liver parenchyma, the aorta, and the portal vein in individuals diagnosed with primary hepatocellular carcinoma.

Simultaneous Image Reconstruction and Element Decomposition for Iodine Contrast Agent Visualization in Multienergy Element-Resolved Cone Beam CT

Iodine contrast agent is widely used in liver cancer radiotherapy at CT simulation stage to enhance detectability of tumor. However, its application in cone beam CT (CBCT) for image guidance before treatment delivery is still limited because of poor image quality and excessive dose of contrast agent during multiple treatment fractions. We previously developed a multienergy element-resolved (MEER) CBCT framework that included x-ray projection data acquisition on a conventional CBCT platform in a kVp-switching model and a dictionary-based image reconstruction algorithm that simultaneously reconstructed x-ray attenuation images at each kilovoltage peak (kVp), an electron density image, and elemental composition images. In this study, we investigated feasibility using MEER-CBCT for low-concentration iodine contrast agent visualization. We performed simulation and experimental studies using a phantom with inserts containing water and different concentrations of iodine solution and the MEER-CBCT scan with 600 projections in a full gantry rotation, in which the kVp level sequentially changed among 80, 100, and 120 kVps. We included iodine material in the dictionary of the reconstruction algorithm. We analyzed iodine detectability as quantified by contrast-to-noise ratio (CNR) and compared results with those of CBCT images reconstructed by the standard filter back projection (FBP) method with 600 projections. MEER-CBCT achieved similar contrast enhancement as FBP method but significantly higher CNR. At 2.5% iodine solution concentration, FBP method achieved 170 HU enhancement and CNR of 2.0, considered the standard CNR for successful tumor visualization. MEER-CBCT achieved the same CNR but at ~6.3 times lower iodine concentration of 0.4%.

Impact of CT Injector Technology and Contrast Media Viscosity on Vascular Enhancement: Evaluation in a Circulation Phantom

Objective:

To assess the impact of piston-based vs peristaltic injection system technology and contrast media viscosity on achievable iodine delivery rates (IDRs) and vascular enhancement in a pre-clinical study.

Methods:

Four injectors were tested: MEDRAD^® Centargo, MEDRAD^® Stellant, CT Exprès^®, and CT motion^™ using five contrast media [iopromide (300 and 370 mgI ml⁻¹), iodixanol 320 mgI ml⁻¹, iohexol 350 mgI ml⁻¹, iomeprol 400 mgI ml⁻¹]. Three experiments were performed evaluating achievable IDR and corresponding enhancement in a circulation phantom.

Results:

Experiment I: Centargo provided the highest achievable IDRs with all tested contrast media (p < 0.05). Iopromide 370 yielded the highest IDR with an 18G catheter (3.15 gI/s); iopromide 300 yielded the highest IDR with 20G (2.70 gI/s) and 22G (1.65 gI/s) catheters (p < 0.05).

Experiment II: with higher achievable IDRs, piston-based injectors provided significantly higher peak vascular enhancement (up to 48% increase) than the peristaltic injectors with programmed IDRs from 1.8 to 2.4 gI/s (p < 0.05).

Experiment III: with programmed IDRs (e.g. 1.5 gI/s) achievable by all injection systems, Centargo, with sharper measured bolus shape, provided significant increases in enhancement of 34–73 HU in the pulmonary artery with iopromide 370 (p < 0.05).

Conclusion:

The tested piston-based injection systems combined with low viscosity contrast media provide higher achievable IDRs and higher peak vascular enhancement than the tested peristaltic-based injectors. With equivalent IDRs, Centargo provides higher peak vascular enhancement due to improved bolus shape.

Advances in knowledge:

This paper introduces a new parameter to compare expected performance among contrast media: the concentration/viscosity ratio. Additionally, it demonstrates previously unexplored impacts of bolus shape on vascular enhancement.

Contrast enhancement efficacy of iodinated contrast media: Effect of molecular structure on contrast enhancement

Purpose

To investigate the contrast enhancement in DSA images based on the X-ray absorption characteristics of iodinated contrast media.

Methods

We have derived a new formula of predicting the pixel value ratio of two different contrast media and designate it as "Contrast Enhancement Ratio (CER)". In order to evaluate the accuracy of CER, we have evaluated the relationship between CER and pixel value ratio for all combinations of eleven iodinated contrast media. The non-ionic iodinated contrast media, iopamidol, iomeprol, iopromide, ioversol, iohexol, and iodixanol, were evaluated in this study. Each contrast medium was filled in the simulated blood vessel in our constructed anthropomorphic phantom, and DSA images were obtained using an angiographic imaging system. To evaluate the contrast enhancement of the contrast medium, the mean pixel value was calculated from all pixel values in the vascular image.

Results

CER was indicated to agree well with the pixel value ratio of two different contrast medium solutions and showed a good accuracy. CER was also shown to have a good linear relation to the pixel value ratio when the iodine concentration was constant. This means that the molecular structure of the contrast media affects contrast enhancement efficacy. Furthermore, in evaluation of contrast enhancement of iodinated contrast media by using the weight factor (that is a key factor in CER) ratio, Iodixanol, and iopamidol, and iomeprol have the same ability of contrast enhancement in DSA images, and iohexol shows the lowest ability.

Conclusions

We have derived a new formula (CER) of predicting the pixel value ratio of two different contrast medium solutions, and shown that CER agreed well with the pixel value ratio for blood vessel filled with eleven contrast media.

Large-Scale Synthesis and Medical Applications of Uniform-Sized Metal Oxide Nanoparticles

Thanks to recent advances in the synthesis of high-quality inorganic nanoparticles, more and more types of nanoparticles are becoming available for medical applications. Especially, metal oxide nanoparticles have drawn much attention due to their unique physicochemical properties and relatively inexpensive production costs. To further promote the development and clinical translation of these nanoparticle-based agents, however, it is highly desirable to reduce unwanted interbatch variations of the nanoparticles because characterizing and refining each batch are costly, take a lot of effort, and, thus, are not productive. Large-scale synthesis is a straightforward and economic pathway to minimize this issue. Here, the recent achievements in the large-scale synthesis of uniform-sized metal oxide nanoparticles and their biomedical applications are summarized, with a focus on nanoparticles of transition metal oxides and lanthanide oxides, and clarifying the underlying mechanism for the synthesis of uniform-sized nanoparticles. Surface modification steps to endow hydrophobic nanoparticles with water dispersibility and biocompatibility are also briefly described. Finally, various medical applications of metal oxide nanoparticles, such as bioimaging, drug delivery, and therapy, are presented.

Triple-phase MDCT of liver: Scan protocol modification to obtain optimal vascular and lesional contrast

Context:

With advances in 16-slice multidetector computed tomography (MDCT), the entire liver can be scanned in 4–6 s and a single breath-hold dual-phase scan can be performed in 12–16 s. Consequently, optimizing the scan window has become critical.

Aim:

The purpose of our study was to optimize scan delays using bolus-tracking techniques for triple-phase CT of the liver.

Settings and Design:

Fifty patients with liver lesions were randomly divided into two groups with 25 patients each. The patients were subjected to triple-phase MDCT of liver with two different scan protocols.

Materials and Methods:

They were administered 1.5 mL/kg of 300 mg/mL of iohexol at a rate of 3.0 mL/s with a pressure injector. Using bolus-tracking program, scans were commenced at 4, 19, and 44 s and 8, 23, and 48 s for the first, second, and third phases, respectively. The mean CT values [Hounsfield unit (HU)] were measured in the aorta, hepatic artery, portal vein, hepatic vein, liver parenchyma, and lesion using circular region of interest cursor ranging in size from 5 to 20 mm in diameter on all phases.

Statistical Analysis Used:

Statistical analysis was carried out using paired Student's t-test.

Results:

In hepatic arterial phase, hepatic artery has shown better enhancement in Group B (8 s) (P = 0.0498) compared with Group A (4 s). In portal venous phase, there were no significant differences in contrast enhancement index (CEI) values at any of the six measured regions between the groups. In the hepatic venous phase, liver parenchyma has shown nearly significant (P = 0.0664) higher CEI values in Group B (48 s) when compared with Group A (44 s).

Conclusion:

A scan delay of 8 s, after trigger threshold (100 HU) is reached in the lower thoracic aorta, is optimal for the early arterial phase imaging, this phase being most helpful for assessment of hepatic arterial tree (CT angiography). The liver parenchyma showed maximum enhancement at 48 s scan delay.

An Individually Optimized Protocol of Contrast Medium Injection in Enhanced CT Scan for Liver Imaging

Objective

To investigate the effectiveness of a new individualized contrast medium injection protocol for enhanced liver CT scan.

Methods

324 patients who underwent plain and dual phase enhanced liver CT were randomly assigned to 2 groups: G1 (n = 224, individualized contrast medium injection protocol); G2 (n = 100, standard contrast medium injection with a dose of 1.5 ml/kg). CT values and ΔHU (CT values difference between plain and enhanced CT) of liver parenchyma and tumor-liver contrast (TLC) during hepatic arterial phase (HAP) and portal venous phase (PVP) and contrast medium dose were measured. The tumor conspicuity of hepatocellular carcinoma (HCC) between two groups was independently evaluated by two radiologists.

Results

The mean contrast medium dose of G1 was statistically lower than that of G2. There were no significantly statistical differences in CT values and ΔHU of liver parenchyma during HAP, TLC values during HAP, and PVP between two groups. The CT values and ΔHU of liver parenchyma during PVP of G2 were significantly higher than those of G1. Two independent radiologists were both in substantial conformity in grading tumor conspicuity.

Conclusion

Using the individually optimized injection protocol might reduce contrast medium dose without impacting on the imaging quality in enhanced liver CT.